U.S. Pharmaceuticals & Biotech Mid-Large Cap Stocks

Bristol-Myers Squibb

Market Cap: US$118.7b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Johnson & Johnson

Market Cap: US$633.2b

Engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.

Zoetis

Market Cap: US$31.4b

Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.

Amgen

Market Cap: US$201.9b

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Gilead Sciences

Market Cap: US$163.0b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Merck

Market Cap: US$320.0b

Operates as a healthcare company worldwide.

AbbVie

Market Cap: US$461.3b

A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

Agilent Technologies

Market Cap: US$36.9b

Provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.

Phibro Animal Health

Market Cap: US$1.3b

Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.

Pfizer

Market Cap: US$138.6b

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Perrigo

Market Cap: US$1.5b

Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.

Danaher

Market Cap: US$140.1b

Designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.

Royalty Pharma

Market Cap: US$33.3b

Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.

Viatris

Market Cap: US$19.4b

Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.

Qiagen

Market Cap: US$8.3b

Provides sample to insight solutions that transform biological samples into molecular insights worldwide.

AnaptysBio

Market Cap: US$1.8b

A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.

Hisamitsu Pharmaceutical

Market Cap: US$8.2b

Manufactures and sells pharmaceuticals in Japan.

Corcept Therapeutics

Market Cap: US$9.7b

A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

Arcus Biosciences

Market Cap: US$3.8b

A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

TG Therapeutics

Market Cap: US$7.6b

A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

Tempus AI

Market Cap: US$10.8b

Operates as a healthcare technology company in the United States.

Sarepta Therapeutics

Market Cap: US$2.0b

A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.

Revolution Medicines

Market Cap: US$40.2b

A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.

Organon

Market Cap: US$3.6b

Develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.

Intellia Therapeutics

Market Cap: US$2.5b

Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

Kodiak Sciences

Market Cap: US$2.4b

A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

Travere Therapeutics

Market Cap: US$5.3b

A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.

Olema Pharmaceuticals

Market Cap: US$1.1b

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.

ACADIA Pharmaceuticals

Market Cap: US$4.4b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

Septerna

Market Cap: US$1.5b

A clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.

Capricor Therapeutics

Market Cap: US$1.3b

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Avantor

Market Cap: US$7.0b

Engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.

Amylyx Pharmaceuticals

Market Cap: US$2.0b

A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.

ADMA Biologics

Market Cap: US$2.1b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Adaptive Biotechnologies

Market Cap: US$3.4b

A commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.

Stevanato Group

Market Cap: US$5.2b

Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.